Aquestive Therapeutics (AQST)

• Market cap: $284M
• 1 day: -5.59%
• 5 days: -10.03%
• 1 month: 8.30%
• 3 months: -19.83%
• 6 months: -38.68%
• Year to date: -21.80%
• 1 year: -34.47%
• 5 years: 55.98%
• 10 years: -82.12%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

Employees: 142

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

212% more call options, than puts

Call options by funds: $1.89M | Put options by funds: $605K

29% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 34

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

5% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 22

3% less funds holding

Funds holding: 117 [Q3] → 114 (-3) [Q4]

3.84% less ownership

Funds ownership: 51.42% [Q3] → 47.57% (-3.84%) [Q4]

34% less capital invested

Capital invested by funds: $233M [Q3] → $155M (-$78M) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $8 179% upside
• Avg. target: $9 214% upside
• High target: $10 248% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Raghuram Selvaraju 26% 1-year accuracy 18 / 70 met price target	248% upside $10	Buy Reiterated	2 Apr 2025
Lake Street Thomas Flaten 50% 1-year accuracy 5 / 10 met price target	179% upside $8	Buy Maintained	7 Mar 2025